CORDIS
EU research results

CORDIS

English EN

Identification of Novel Targeted Therapies for Renal Cancer

Project information

Grant agreement ID: 323004

Status

Closed project

  • Start date

    1 September 2013

  • End date

    31 August 2018

Funded under:

FP7-IDEAS-ERC

  • Overall budget:

    € 2 247 890,24

  • EU contribution

    € 2 247 890,24

Hosted by:

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

Objective

"Overall, kidney cancers are the eighth most common cancer and the incidence of the most common form (renal cell carcinoma, RCC) has been increasing steadily over the past 30 years. If detected early, surgical removal of RCC can be curative but the prognosis for metastatic disease is very poor. RCC is resistant to conventional therapy and recently introduced targeted therapies form the mainstay of treatment for metastatic disease. The rationale for the use of targeted therapies (e.g. antiangiogenic tyrosine kinase inhibitors) in RCC was derived from functional investigations of the mechanism of tumourigenesis in the rare inherited RCC syndrome von Hippel-Lindau disease. Whilst currently available targeted therapies can extend progression free survival in advanced RCC they are not curative and better treatments are urgently required. Large scale genomic studies of RCC are in progress and will greatly enhance current knowledge of the molecular pathology of RCC. However, experience from other cancers suggests that the results of genomic analyses of cancer are complex and identifying the key “gatekeeper genes” is frequently challenging. ONCOTREAT is based on the hypothesis that (a) the identification of the genetic basis of inherited forms of RCC will highlight those genes and pathways that are critical for tumourigenesis and (b) that selective targeting of cells deficient in inherited RCC gene function will enable advances in the treatment of inherited and sporadic RCC.
The objectives of ONCOTREAT are to:
1. Identify novel inherited RCC genes
2. Generate and characterise human cell line models for inherited RCC genes
3. Identify candidate therapeutic agents that, in in vitro studies, selectively target human cell line models of inherited RCC genes dysfunction
4. Evaluate candidate therapeutic agents identified from in vitro studies in in vivo investigations to identify agents that target cancers deficient in inherited RCC gatekeeper genes."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Principal Investigator

Eamonn Richard Maher (Prof.)

Host institution

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

Address

Trinity Lane The Old Schools
Cb2 1tn Cambridge

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 231 739,80

Principal Investigator

Eamonn Richard Maher (Prof.)

Administrative Contact

Renata Schaeffer (Ms.)

Beneficiaries (2)

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 2 231 739,80

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 16 150,44

Project information

Grant agreement ID: 323004

Status

Closed project

  • Start date

    1 September 2013

  • End date

    31 August 2018

Funded under:

FP7-IDEAS-ERC

  • Overall budget:

    € 2 247 890,24

  • EU contribution

    € 2 247 890,24

Hosted by:

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom